Literature DB >> 28656554

Fluconazole Non-susceptible Cryptococcus neoformans, Relapsing/Refractory Cryptococcosis and Long-term Use of Liposomal Amphotericin B in an AIDS Patient.

Rodrigo de Carvalho Santana1, Letícia Aparecida Schiave2, Alda Soares Dos Santos Quaglio2, Cristiane Masetto de Gaitani3, Roberto Martinez2.   

Abstract

The treatment of cryptococcosis is hampered by inefficacy or intolerance to the recommended antifungal agents. A patient diagnosed with AIDS had multiple relapses of cryptococcal infection, which became refractory to antifungal agents during the course of therapy. During the follow-up, the patient developed renal toxicity due to amphotericin B use and non-susceptibility of isolated Cryptococcus neoformans to fluconazole was detected. Thereafter, antifungal treatment was performed exclusively with liposomal amphotericin B, reaching a cumulative dose of 19,180 mg over 46 months. The final relapse of cryptococcosis occurred during the maintenance phase with liposomal formulation in a once-weekly dose. Measurement of the minimum serum concentrations of amphotericin B, determined sequentially before and after this relapse, suggested the importance of monitoring drug levels when the liposomal formulation is used for a long period.

Entities:  

Keywords:  Antifungal susceptibility; Cryptococcal meningitis; Cryptococcus; Fluconazole; Liposomal amphotericin B

Mesh:

Substances:

Year:  2017        PMID: 28656554     DOI: 10.1007/s11046-017-0165-1

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  21 in total

1.  Response to therapy in patients with cryptococcosis and AIDS: Association with in vitro susceptibility to fluconazole.

Authors:  Carlos Andrés Agudelo; Carolina Muñoz; Alex Ramírez; Angela María Tobón; Catalina de Bedout Bact; Luz Elena Cano; Angela Restrepo
Journal:  Rev Iberoam Micol       Date:  2014-11-28       Impact factor: 1.044

2.  Refractory and/or Relapsing Cryptococcosis Associated with Acquired Immune Deficiency Syndrome: Clinical Features, Genotype, and Virulence Factors of Cryptococcus spp. Isolates.

Authors:  Erika Nascimento; Lucia H Vitali; Ludmilla Tonani; Marcia R Von Zeska Kress; Osvaldo M Takayanagui; Roberto Martinez
Journal:  Am J Trop Med Hyg       Date:  2016-02-29       Impact factor: 2.345

3.  Cryptococcal meningitis in HIV-infected patients: a longitudinal study in Cambodia.

Authors:  Emmanuelle Espié; Loretxu Pinoges; Suna Balkan; Ngeth Chanchhaya; Lucas Molfino; Prak Narom; Mar Pujades-Rodríguez
Journal:  Trop Med Int Health       Date:  2010-09-25       Impact factor: 2.622

4.  Very prolonged liposomal amphotericin B use leading to a lysosomal storage disease.

Authors:  J M Michot; C Gubavu; E Fourn; G Maigne; E Teicher; A Angoulvant; S Blanche; O Lortholary; A Coilly; J C Duclos-Vallée; M Sebagh; C Guettier; C Aumont; J F Delfraissy; O Lambotte
Journal:  Int J Antimicrob Agents       Date:  2014-04-12       Impact factor: 5.283

5.  Correlation of fluconazole MICs with clinical outcome in cryptococcal infection.

Authors:  A I Aller; E Martin-Mazuelos; F Lozano; J Gomez-Mateos; L Steele-Moore; W J Holloway; M J Gutiérrez; F J Recio; A Espinel-Ingroff
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

Review 6.  Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries.

Authors:  Angela Loyse; Harry Thangaraj; Philippa Easterbrook; Nathan Ford; Monika Roy; Tom Chiller; Nelesh Govender; Thomas S Harrison; Tihana Bicanic
Journal:  Lancet Infect Dis       Date:  2013-06-02       Impact factor: 25.071

7.  Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

Authors:  John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

8.  Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.

Authors:  A Espinel-Ingroff; A I Aller; E Canton; L R Castañón-Olivares; A Chowdhary; S Cordoba; M Cuenca-Estrella; A Fothergill; J Fuller; N Govender; F Hagen; M T Illnait-Zaragozi; E Johnson; S Kidd; C Lass-Flörl; S R Lockhart; M A Martins; J F Meis; M S C Melhem; L Ostrosky-Zeichner; T Pelaez; M A Pfaller; W A Schell; G St-Germain; L Trilles; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2012-09-04       Impact factor: 5.191

9.  Increasing trend of fluconazole-non-susceptible Cryptococcus neoformans in patients with invasive cryptococcosis: a 12-year longitudinal study.

Authors:  Yi-Chun Chen; Tzu-Yao Chang; Jien-Wei Liu; Fang-Ju Chen; Chun-Chih Chien; Chen-Hsiang Lee; Cheng-Hsien Lu
Journal:  BMC Infect Dis       Date:  2015-07-22       Impact factor: 3.090

10.  Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study.

Authors:  Françoise Dromer; Simone Mathoulin-Pélissier; Odile Launay; Olivier Lortholary
Journal:  PLoS Med       Date:  2007-02       Impact factor: 11.069

View more
  5 in total

Review 1.  Cryptococcus spp. and Cryptococcosis: focusing on the infection in Brazil.

Authors:  Fabíolla Nacimento do Carmo; Juliana de Camargo Fenley; Maíra Terra Garcia; Rodnei Dennis Rossoni; Juliana Campos Junqueira; Patrícia Pimentel de Barros; Liliana Scorzoni
Journal:  Braz J Microbiol       Date:  2022-04-29       Impact factor: 2.214

Review 2.  Cryptococcus neoformans and Cryptococcus gattii Species Complexes in Latin America: A Map of Molecular Types, Genotypic Diversity, and Antifungal Susceptibility as Reported by the Latin American Cryptococcal Study Group.

Authors:  Carolina Firacative; Wieland Meyer; Elizabeth Castañeda
Journal:  J Fungi (Basel)       Date:  2021-04-09

Review 3.  The status of cryptococcosis in Latin America.

Authors:  Carolina Firacative; Jairo Lizarazo; María Teresa Illnait-Zaragozí; Elizabeth Castañeda
Journal:  Mem Inst Oswaldo Cruz       Date:  2018-04-05       Impact factor: 2.743

4.  Clinical and microbiological characteristics of cryptococcosis at an university hospital in China from 2013 to 2017.

Authors:  Lan-Fang Fang; Piao-Piao Zhang; Jie Wang; Qing Yang; Ting-Ting Qu
Journal:  Braz J Infect Dis       Date:  2019-12-20       Impact factor: 3.257

5.  Fluconazole levels in serum and cerebrospinal fluid according to daily dosage in patients with cryptococcosis and other fungal infections.

Authors:  Letícia Aparecida Schiave; Erika Nascimento; Fernando Crivelenti Vilar; Tissiana Marques de Haes; Osvaldo Massaiti Takayanagui; Cristiane Masetto de Gaitani; Roberto Martinez
Journal:  Braz J Infect Dis       Date:  2017-11-13       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.